DCT

1:26-cv-00471

Bayer IP GmbH v. Rosemont Pharma Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00471, D. Del., 04/23/2026
  • Venue Allegations: Venue is alleged to be proper for Defendant Rosemont Pharmaceuticals Holdings, Inc. as it is a Delaware corporation, and for Defendant Rosemont Pharmaceuticals Limited as it is not a U.S. resident and is subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of a New Drug Application (NDA) to the FDA for generic versions of the anticoagulant drug XARELTO® constitutes an act of infringement of a patent covering a specific method of using the drug.
  • Technical Context: The technology relates to oral anticoagulant therapies, specifically Factor Xa inhibitors used for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and stroke.
  • Key Procedural History: The lawsuit is a Hatch-Waxman action initiated under 35 U.S.C. § 271(e)(2), triggered by Defendant Rosemont's submission of NDA No. 221033 with a Paragraph IV certification, challenging U.S. Patent No. 9,539,218. Plaintiffs were notified of the submission via a letter dated March 9, 2026.

Case Timeline

Date Event
2005-01-31 '218 Patent Priority Date
2017-01-10 '218 Patent Issue Date
2026-03-09 Rosemont Notice Letter Sent
2026-04-23 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,539,218 - Prevention and Treatment of Thromboembolic Disorders

The Invention Explained

  • Problem Addressed: The patent's background describes the disadvantages of prior art anticoagulants (blood thinners) Compl. Ex. A, '218 Patent, col. 1:59 - col. 2:20 Heparin-based drugs typically require parenteral (non-oral) administration, while oral vitamin K antagonists like warfarin have a slow onset of action and a narrow therapeutic index, requiring frequent patient monitoring to balance efficacy and bleeding risk '218 Patent, col. 1:59 - col. 2:20
  • The Patented Solution: The patent claims a method of treating certain thromboembolic disorders by administering the direct Factor Xa inhibitor rivaroxaban "no more than once daily" '218 Patent, claim 1 The specification presents as surprising the finding that a once-daily regimen is effective for an inhibitor with a short plasma half-life (under 10 hours), a characteristic that would typically suggest more frequent (e.g., twice or thrice daily) administration to maintain therapeutic levels '218 Patent, col. 2:40-52 '218 Patent, col. 2:64 - col. 3:2
  • Technical Importance: The invention purports to provide the convenience and improved patient compliance of a once-daily oral medication while avoiding the burdensome monitoring associated with older anticoagulants '218 Patent, col. 2:35-39

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 1 ('Compl. ¶33; Compl. ¶35).
  • Independent claim 1 of the '218 Patent requires:
    • A method of treating a thromboembolic disorder selected from pulmonary embolisms, deep vein thromboses, and stroke.
    • The method comprises administering a specific direct Factor Xa inhibitor, 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (rivaroxaban).
    • Administration is "no more than once daily."
    • Administration occurs "for at least five consecutive days."
    • The drug is delivered in a "rapid-release tablet."
  • The complaint does not assert any dependent claims but may reserve the right to do so.

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are "Rosemont's NDA Products," which are generic versions of Plaintiffs' XARELTO® (rivaroxaban) products for which Rosemont submitted NDA No. 221033 to the FDA Compl. ¶1 Compl. ¶9

Functionality and Market Context

The products are oral anticoagulant drugs containing rivaroxaban as the active ingredient Compl. ¶32 The infringement allegation is not based on current commercial sales, but rather on the submission of the NDA seeking FDA approval to market a generic product for indications allegedly covered by the '218 Patent Compl. ¶1 Compl. ¶48 The complaint alleges that Rosemont's proposed product labeling directs the use of the generic product for treating thromboembolic disorders such as deep vein thrombosis and pulmonary embolism, which are recited in the asserted patent claim Compl. ¶34

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that the use of Rosemont's NDA Products, as directed by their proposed labeling, will infringe at least claim 1 of the '218 Patent Compl. ¶33

'218 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating a thromboembolic disorder ... wherein the thromboembolic disorder is selected from the group consisting of pulmonary embolisms, deep vein thromboses, and stroke. Rosemont's proposed product labeling allegedly directs its use for treating, among other things, deep vein thrombosis (DVT) and pulmonary embolism (PE). ¶34 col. 12:3-6
administering a direct factor Xa inhibitor that is 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide Rosemont's notice letter allegedly stated that its NDA Products contain rivaroxaban, the chemical compound identified in the claim. ¶32 col. 11:67-col. 12:3
no more than once daily The proposed labeling for Rosemont's NDA Products allegedly directs a use that satisfies the "no more than once daily" dosage requirement. ¶34 col. 12:1
for at least five consecutive days The proposed labeling allegedly directs a use that satisfies the "at least five consecutive days" requirement. ¶34 col. 12:1-2
in a rapid-release tablet The complaint alleges infringement of claim 1, which contains this limitation, implying the accused generic is a rapid-release tablet. ¶33; ¶35 col. 12:2

Identified Points of Contention

  • Inducement Scope Question: Given that infringement is based on inducement via a product label, a central question will be whether Rosemont's proposed label directs users to perform every step of the claimed method for at least one of the three specific disorders (pulmonary embolism, deep vein thrombosis, or stroke) recited in claim 1.
  • Technical Question: A potential dispute may arise over whether Rosemont's generic product meets the patent's specific definition of a "rapid-release tablet," which is defined by a particular dissolution profile under a specific USP testing method '218 Patent, col. 7:21-24 The complaint does not provide technical details on the accused product's formulation.

V. Key Claim Terms for Construction

  • The Term: "rapid-release tablet"
  • Context and Importance: This term is critical because if Rosemont's product does not meet the definition of a "rapid-release tablet," there can be no literal infringement of claim 1. Practitioners may focus on this term because the patent provides a specific, technical definition that may serve as a clear basis for non-infringement if the accused product's dissolution profile differs.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party could argue for a more general, plain-and-ordinary meaning if any ambiguity can be found in the specification's definition.
    • Evidence for a Narrower Interpretation: The specification appears to act as its own lexicographer, stating: "In the context of the present invention, rapid-release tablets are in particular those which, according to the USP release method using apparatus 2 (paddle), have a Q value (30 minutes) of 75%" '218 Patent, col. 7:21-24 This language strongly supports a narrow construction limited to tablets meeting this specific technical standard.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges active inducement of infringement, stating that Rosemont's proposed product labeling will instruct and encourage physicians and patients to administer the generic drug in an infringing manner Compl. ¶41 It further alleges contributory infringement, claiming that Rosemont's products are "especially made or adapted for use in infringing the '218 patent" and are not suitable for substantial noninfringing use Compl. ¶42
  • Willful Infringement: The complaint does not use the term "willful," but it alleges that Rosemont has "knowledge of the claims of the '218 patent" from, at a minimum, its Paragraph IV certification Compl. ¶36 Compl. ¶40 Plaintiffs seek a declaration that the case is "exceptional" and an award of attorneys' fees pursuant to 35 U.S.C. § 285, which is often associated with findings of willful infringement or other litigation misconduct Compl., Prayer (e)

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary issue will be one of validity, specifically obviousness: Was it obvious to try a once-daily dosing regimen for a Factor Xa inhibitor like rivaroxaban, which was known to have a short plasma half-life that would conventionally suggest more frequent administration? The patent's assertion that the once-daily efficacy was surprising will likely be a central point of contention.
  • A key question for infringement will be one of technical definition: Does the accused generic product's formulation meet the specific dissolution profile required by the patent's explicit definition of a "rapid-release tablet"? The outcome of this claim construction and the subsequent factual analysis could be dispositive.
  • A third core issue will concern induced infringement: Does the language of the defendant's proposed product label, which forms the basis for this Hatch-Waxman suit, unambiguously direct or encourage clinicians and patients to administer the drug in a manner that practices every element of the asserted claim, including the specific dosage frequency, duration, and patient population?
Loading Complaint